| viXra.org > Biochemistry > 2003 |
 |
 |
| viXra.org > Biochemistry > 2003 |
|
|
[4] viXra:2003.0618 [pdf] submitted on 2020-03-28 04:33:27
Authors: H. Dhaliwal
Comments: 1 Page.
There are several published accounts of 100+ year old patients that have recovered from COVID-19. These 100+ year old COVID-19 infected and recovered patients were infants during the 1918 Spanish flu and may have been exposed to the virus. It may be possible that they have developed antibodies to the Spanish Flu which may be effective against COVID-19 or have had an immune response that was able to survive COVID-19. A vaccine or antibodies targeting the Spanish Flu, or any viruses similar to the Spanish Flu such as Swine Flu or H1N1 may be a potential treatment or preventative treatment for COVID-19. Further research is required.
Category: Biochemistry
[3] viXra:2003.0455 [pdf] submitted on 2020-03-21 14:58:11
Authors: Neel Adwani, Salomé Urien, Vijay B., Jullianne B., Veronica Donato
Comments: 15 Pages.
The genetic conditions are affecting 1 American over 10, and a total of 350 million people around the world. 80% of those are caused by faulty genes. First we plan to track each person genetic path by using big data. When the newborn will be declared, a sample of blood will be preleved to analyse his DNA and all the informations about his genome will be transferred to a global network. An informatic program will identify where anomalies are on the molecule and create an algorithm to signalize where a modification need to occur and which one. With the algorithm the nanotubes will identify the exact place and fix the nitrogenous base to form the right nucleotide when the DNA is duplicating.
Category: Biochemistry
[2] viXra:2003.0445 [pdf] submitted on 2020-03-21 04:21:43
Authors: Arturo Tozzi
Comments: 8 Pages.
Here we suggest three feasible options that could be useful in COVID-19 medical management.
Category: Biochemistry
[1] viXra:2003.0125 [pdf] submitted on 2020-03-05 23:54:18
Authors: Shazia Tahira
Comments: 9 Pages.
Pancreatic adenocarcinoma is not the most frequent cancer, but it is one of the deadliest cancers. The 5-year survival rate is 9% only. It is usually diagnosed at a later stage when surgical resection is not possible and metastases have already spread to other parts of the body. Developing early screening tools can help in diagnosing pancreatic cancer at initial and earlier stages when surgical resection is still a possibility leading to more years of survival and a potential cure. Different studies show the importance of identification of pancreatic carcinoma before large growth in tumor size. Recurrence after surgery is late if serum tumor marker level is comparatively less, tumor size is small and it is localized with no lymph node or vascular invasion and so according to different studies, early detection of tumor lead to more median survival time. There are many pancreatic carcinoma serum tumor markers, but most of them do not improve upon CA19-9 which is considered a gold standard pancreatic carcinoma serum marker although CA 19-9 also does not have perfect sensitivity and specificity. Because of less than 100% sensitivity and specificity, screening tests, using serum markers are mostly not recommended for the general population, although they are recommended for high-risk populations. Here we present a brief review about Ca 19-9 and some other pancreatic adenocarcinoma serum tumor markers including THBS2, MIC-1, sTRA, CEACAM1, CA 494, Span-1 and PAM4 which show some improvement over CA19-9. CA 19-9 is considered the standard pancreatic adenocarcinoma serum tumor marker but there are other pancreatic adenocarcinoma serum tumor markers with comparatively better sensitivity and specificity. THBS2 has comparatively less sensitivity but better specificity compared to CA 19-9. PAM4 has comparatively less or equal sensitivity but better specificity compared to CA 19-9. CEACAM1 and CA 494 have comparatively better sensitivity and specificity compared to CA 19-9. Span-1 has comparatively better sensitivity but less or equal specificity compared to CA19-9. MIC-1 has comparatively better sensitivity but less specificity compared to CA 19-9. sTRA has comparatively better sensitivity and equal specificity, also it is secreted by pancreatic adenocarcinoma cells which are different from those which secrete CA19-9. There is a possibility that a combination of these serum markers in screening tests may yield more sensitive and specific results that can be used for screening high risk as well as the general population.
Category: Biochemistry
| Third-Party Links: |
|